When was IASO BIO founded?

IASO BIO was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is IASO BIO located?

IASO BIO is headquartered in Nanjing, China.

Who is the current CEO of IASO BIO?

Jinhua Zhang of IASO BIO. They have also founded 1 company.

How many employees does IASO BIO have?

As of Aug 31, 2026, the latest employee count at IASO BIO is 54.

Is IASO BIO a funded company?

IASO BIO is a funded company, having raised a total of $178M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Mar 23, 2020.

When was the latest funding round of IASO BIO?

IASO BIO's latest funding was a $***** Series C round on Jan 18, 2023, with participation from 7 investors. Its primary sector is Oncology. In China, the Oncology sector has seen $765M in funding in 2026 to date.

Where does IASO BIO rank among its competitors?

IASO BIO ranks 249th amongst 3389 active competitors, of which 1127 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of IASO BIO?

IASO BIO's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

IASO BIO - 2026 Company Profile, Team, Funding, Competitors & Financials

IASO BIO is a series C company based in Nanjing (China), founded in 2017 by Jinhua Zhang. It operates as a Provider of pharmaceuticals for cell therapies for oncology. IASO BIO has raised $178M in funding from investors like CDH, CoStone Capital and CCB International. The company has 3389 active competitors, including 1127 funded and 783 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Provider of pharmaceuticals for cell therapies for oncology. Its technology involves CAR-T cell therapeutics for hematological malignant and its candidate like CT1038, RD102 and others.

Website: iasobio.com
Phone Number: +86 **********

Key Metrics

Founded Year

2017

Location

Nanjing, China

Stage

Series C

Total Funding

$178M in 3 rounds

Latest Funding Round

Series C, Jan 18, 2023, $*****

Investors

CDH & 14 more

Ranked

249^th among 3389 active competitors

Employee Count

54 as on Aug 31, 2026

Investment & Acquisitions

Medisix Therapeutics

Similar Companies

Jazz Pharmaceuticals & 3013 more

View IASO BIO's full profile

IASO BIO is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
IASO BIOMED, INC. CIN: 1662907 , United States, Active		-	-	-

IASO BIO has raised a total funding of $178M over 3 rounds. Its first funding round was on Mar 23, 2020. Its latest funding round was a Series C round on Jan 18, 2023 for $*****. 7 investors participated in its latest round. IASO BIO has 15 institutional investors.

Here is the list of recent funding rounds of IASO BIO:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 18, 2023	4022670	Series C	2092169	7810651	1955600	8145858
Sep 16, 2021	9358949	Series C	9800928	6464503	2337481	6578444
Mar 23, 2020	7189753	Series B	4163544	1915798	Hillhouse	8533255

Access funding benchmarks and valuations. Sign up today!

View details of IASO BIO's funding rounds and investors

The founders of IASO BIO is Jinhua Zhang. Jinhua Zhang is the CEO of IASO BIO.

Here are the details of IASO BIO's key team members:

Jinhua Zhang: Co-Founder & CEO of IASO BIO.
Contact Info: 1 email address

View details of IASO BIO's Founder profiles and Board Members

IASO BIO's employee count trend

IASO BIO has 54 employees as of Aug 26. Here is IASO BIO's employee count trend over the years:

Uncover IASO BIO's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of IASO BIO include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of IASO BIO, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
249th	IASO BIO 2017, Nanjing (China), Series C	Provider of pharmaceuticals for cell therapies for oncology	$178M	Hillhouse, CCB International & 13 others	58/100